

# Ballot Language

## General Ballot Instructions

Please mark your choices on the ballot below and click "Preview Ballot" when you are done.

## Positions

### President-Elect

Select 1

Write Ins **Disabled**

**Group Requirement:** All Members

#### **Terrence Monks**

**Assistant Vice-President for Research, Integrated Biosciences, Wayne State University, and Professor, Pharmaceutical Sciences, Eugene Applebaum College of Health Sciences, Wayne State University**

**Personal Statement:** It is an honor to be nominated to serve as the president of ASPET. These are challenging times for biomedical science, but they are also exciting. Indeed, I feel fortunate to be in science at this moment; the intellectual and technical advances being made are truly amazing, and inspire us to experimentally address questions that were simply beyond us just a few years ago. But what of those challenges, and what do they hold for our Society and for our discipline?

There is concern that the assimilation of academic pharmacology departments into more integrated Basic Science departments may erode the identity of pharmacology. Yet such changes create opportunities for pharmacologists to apply their expertise and breadth of knowledge to influence the direction on medical and graduate education. Indeed, pharmacologists, by our very training, have a broad knowledge base and an appreciation of other disciplines. Such diversity of expertise within our discipline is reflected, for example, in the number and variety of ASPET Divisions. However, we need to be careful not to silo ourselves, but continue to encourage scientific programming that not only transcends the interests of specific ASPET Divisions, but that reaches across disciplinary borders. It is usually at the interface between disciplines that the most exciting science takes place and discoveries are made. Thus, prioritizing a vibrant scientific program at the annual meeting is essential to showcase the scientific breadth and rigor of our discipline, and will be a priority of my tenure as ASPET president.

Scientific rigor and reproducibility are also of major concern, and ASPET should be a leader in addressing this real problem. As president I will ensure that ASPET works with other scientific societies and stakeholders to tackle this issue, and provide guidance to our members with respect to appropriate standards of rigor, from experimental design and reagent verification through data analysis and interpretation. ASPET journal editors and editorial boards will also be engaged in this process to

ensure that ASPET journals publish papers that meet these rigorous standards. Critiquing our own work is the best way to demonstrate the rigor that pharmacologists bring to their research.

Support of graduate training in pharmacology has always been, and should continue to be, a priority and strength of our Society. Through travel grants, poster and platform sessions, participation in society governance, ASPET and its members have provided mentorship to countless numbers of graduate students, post-doctoral fellows, and those on the first few steps of the career ladder. These experiences, and the building of a network of peer support have, in no small part, been major contributors to the career success of pharmacologists, whose broad training appeals to many types of employers. Strong support of graduate education and career mentoring remains critical to the future of our discipline, and we should be positive in what the future holds. Crucially, the value of a graduate education has never been greater, with all growth in the "College Wage Premium" since 2000 being due to the earnings of those with advanced degrees. Students are aware of this, and first-time graduate enrollment in health sciences in 2014 grew by 6.1% year-on-year, and occupations typically requiring a graduate degree for entry are forecast to grow the fastest through 2024. As your president I will ensure that ASPET further explore innovative ways in which academia, government, and industry can combine our expertise to ensure that graduate programs continue to produce pharmacology graduates with the problem-solving and communication skills necessary to lead teams with diverse skill sets. The ASPET supported Pharmacology Industry Internships are an excellent example of how our Society can partner in this way to enhance career opportunities.

Finally, how can ASPET better serve its members? How can we improve the programs and services that ASPET currently provide, or create those we currently do not provide? We should certainly be creating programs/workshops that ensure we assist members in all sectors of employment to advance their careers. Conversely, how can you help your Society? Any Society is as strong as its members. For those of you who have yet to enjoy working with your colleagues in ASPET to advance the discipline of pharmacology, I highly encourage you to get involved, to volunteer, to express your opinions, make yourself heard. Respect for diversity of opinions is critical to the success of any organization, and as your president I will actively seek and encourage input from ASPET members and staff alike.

**Edward Morgan**  
**Professor of Pharmacology, Emory University School of Medicine**

**Personal Statement:** One of the first questions job candidates are asked is: Why do you want this position? For me, the answer is easy. I've been a pharmacologist since my undergraduate studies on serotonin action in pig splenic capsule at the University of Glasgow, and ASPET is my scientific and intellectual home. I just received my certificate for 25 years of membership in ASPET, and for the last 18 years I've been actively involved in one aspect or another of program service and leadership. The Society has played a huge role in my career through scientific, networking and leadership opportunities, and it's been a great source of professional and personal satisfaction. I'm excited and energized by this opportunity.

The last decade has been one of extraordinary activity in the Society. The wise investments of our financial assets together with a period of bull markets have put us in a strong financial position. We've used this bounty to benefit our members and our discipline: strengthening the Divisions through increased budgets; increasing the numbers of student and young scientist travel awards; adding the member lounge at the EB meeting; establishing the ASPET-Washington Fellows program; solidifying the endowments of our most prestigious Awards; contributing to the development of the IUPHAR Pharmacology Education Project; adding an Education Manager and a Marketing and Communications Coordinator; rebranding and modernizing ASPET's image; and rebuilding our website. The Big Ideas program empowers the entire membership to envision and implement new initiatives.

All this has been very exciting, but there are challenges we must face. Open Access and the proliferation of journals make the future less predictable for ASPET journals, which are the main source of the Society's income. Sub-disciplines like drug discovery and chemical biology may be impacting society membership and attendance at our conferences. Council has begun a strategic planning process to address these and other pressing issues. It's certain that the incoming President-Elect will need insight into the society's financial structure, its relationship with the journals and the Board of Publications Trustees (BPT), the factors affecting journal income and expenses, and the relationships between the Society and the Divisions. I believe that my experience on the BPT as an at-large member and as Editor of *Drug Metabolism and Disposition*; on two Division Executive Committees and as Chair of the Drug Metabolism Division; as Secretary-Treasurer; and on the Finance Committee and Investments Subcommittee have prepared me very well for this position and for facing these challenges.

Challenges almost always are accompanied by opportunities. The rise of drug discovery and chemical biology have strengthened the impact and importance of pharmacology. We can harness the stimulated interest to our benefit by partnering and synergizing with related societies in sponsoring or presenting conferences and symposia. Such initiatives are already underway, as emphasized by partnerships with our sister societies in China, Britain and Japan. ASPET co-sponsored a meeting with the Academic Drug Discovery Consortium after EB 2016, and I would work to make sure that this type of programming continues so that pharmacologists who are not ASPET members may be stimulated to join. As President, I would ensure that our focus on recruiting and retaining members continues, especially students and early career scientists on whom the continued vitality of the Society depends. The recent formation of the Young Scientists Committee is a great start, and I would work with them to ensure that they are inspired to bring forward programming and initiatives that will help young pharmacologists in choosing and entering a career. I will also work to ensure that those Big Ideas that are successful become part of the regular framework of ASPET.

Membership of ASPET has many benefits such as scientific programming, networking, mentoring, political advocacy, education, free journal subscription and reduced publication costs, travel awards and platforms for young scientists to present and be recognized. While each member assigns their own priorities among them, they are all

vital. However, I'd like to highlight a quote from a respondent to the ASPET member survey. "I think you've left off the most important reason for most people, and the main reason that I joined. I wanted to belong to the premier professional organization in my field of research. Everything else is gravy." (*The Pharmacologist* 57 (4): 238, 2015). I look forward to helping to ensure that ASPET, by paying close attention to all of the above benefits that are important to our members and by shepherding our resources judiciously, continues to be that premier professional organization for nascent and established pharmacologists alike.

## Secretary/Treasurer-Elect

**Select** 1

Write Ins **Disabled**

**Group Requirement:** All Members

**Margaret Gnegy**

**Professor and Associate Chair for Education, Department of Pharmacology,  
University of Michigan Medical School**

**Michael Jarvis**

**Volwiler Senior Research Fellow & Scientific Director, Global Medical Affairs;  
Adjunct Professor of Biopharmaceutical Sciences, University of Illinois, Chicago**

## Councilor

**Select** 1

Write Ins **Disabled**

**Group Requirement:** All Members

**Susan Ingram**

**Associate Professor, Department of Neurological Surgery, Oregon Health &  
Sciences University**

**Alan Smrcka**

**Professor of Pharmacology, University of Michigan Medical School**

**Michael Wood**

**CEO, Neupharm LLC**

## Division for Behavioral Pharmacology Chair-Elect

**Select** 1

Write Ins **Disabled**

**Group Requirement:** BEH

**Jun-Xi Li**

**Associate Professor, University at Buffalo**

## Division for Behavioral Pharmacology Secretary/Treasurer-Elect

**Select** 1

Write Ins **Disabled**

**Group Requirement:** BEH

**Gregory Collins**

**Assistant Professor of Pharmacology, University of Texas Health Science Center at San Antonio**

**Susan Wood**

**Tenure -Track Assistant Professor, University of South Carolina School of Medicine**

## Division for Cardiovascular Pharmacology Chair-Elect

**Select** 1

Write Ins **Disabled**

**Group Requirement:** CVP

**David Busija**

**Regents Endowed Professor and Chair, Department of Pharmacology, Tulane University School of Medicine**

**Fadi Khasawneh**

**Associate Professor and Chair, Department of Pharmaceutical Sciences, School of Pharmacy, The University of Texas at El Paso**

**Hemal Patel**

**Professor and Vice Chair for Research, Department of Anesthesiology, University of California, San Diego**

## Division for Cardiovascular Pharmacology Secretary/Treasurer-Elect

**Select 1**

Write Ins **Disabled**

**Group Requirement:** CVP

**Amy Arnold**

Assistant Professor, Department of Neural and Behavioral Sciences,  
Pennsylvania State University College of Medicine

**Anastasios Lymperopoulos**

Associate Professor of Pharmacology, Nova Southeastern University

**Douglas Tilley**

Assistant Professor, Center for Translational Medicine and Department of  
Pharmacology, Lewis Katz School of Medicine at Temple University

## Division for Drug Discovery and Development Chair-Elect

**Select 1**

Write Ins **Disabled**

**Group Requirement:** DDD

**Craig Beeson**

Professor, Medical University of South Carolina

## Division for Drug Discovery and Development Secretary/Treasurer-Elect

**Select 1**

Write Ins **Disabled**

**Group Requirement:** DDD

**Alvin Terry, Jr.**

Regents Professor and Chair, Department of Pharmacology and Toxicology,  
Medical College of Georgia, Augusta University

Associate Vice President for Basic Science Research, Augusta University

## Division for Drug Metabolism Chair-Elect

**Select 1**

Write Ins **Disabled**

**Group Requirement:** DM

**Xinxin Ding**

**Professor of Nanobioscience, Colleges of Nanoscale Science and Engineering,  
State University of New York Polytechnic Institute**

**Aiming Yu**

**Professor, Department of Biochemistry and Molecular Medicine, University of  
California, Davis**

### **Division for Drug Metabolism Secretary/Treasurer-Elect**

**Select 1**

Write Ins **Disabled**

**Group Requirement:** DM

**Hyunyoung (Young) Jeong**

**Associate Professor, University of Illinois**

**Jed Lampe**

**Assistant Professor, University of Kansas Medical Center**

### **Division for Molecular Pharmacology Chair-Elect**

**Select 1**

Write Ins **Disabled**

**Group Requirement:** MP

**J. Silvio Gutkind**

**Professor, Department of Pharmacology, Associate Director of Basic Science,  
UC San Diego Moores Cancer Center, University of California, San Diego**

**Tracy Handel**

**Professor, Department of Pharmacology, and Skaggs School of Pharmacy and  
Pharmaceutical Sciences (SSPPS); Chair, Division of Pharmaceutical Sciences,  
SSPPS, University of California San Diego**

### **Division for Molecular Pharmacology Secretary/Treasurer-Elect**

**Select 1**

Write Ins **Disabled**

**Group Requirement:** MP

**Yang (Kevin) Xiang**

**Professor, University of California at Davis**

## Division for Pharmacology Education Chair-Elect

**Select 1**

Write Ins **Disabled**

**Group Requirement:** DPE

**A. Laurel Gorman**

Associate Professor Pharmacology and Medical Education, University of Central Florida College of Medicine

Director, Preclinical Medical Pharmacology Curriculum UCF College of Medicine

**Helmut Gottlieb**

Associate Professor, University of the Incarnate Word, Feik School of Pharmacy

## Division for Pharmacology Education Secretary/Treasurer-Elect

**Select 1**

Write Ins **Disabled**

**Group Requirement:** DPE

**Shafiqur Rahman**

Professor of Pharmacology, Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota State University

**Arun Ram**

Associate Professor of Pharmacotherapeutics, Eastern Virginia Medical School, Norfolk, VA; Module Co-Director - Foundational Sciences II of MD Program, EVMS; Course Director - Clinical Pharmacology – for Master of Physician Assistant (MPA) Program, EVMS

## Candidate Biographies

The following biographies were available to voters on the ballot.

### President-Elect - Terrence Monks

**Current Position:** Assistant Vice-President for Research, Integrated Biosciences, Wayne State University, and Professor, Pharmaceutical Sciences, Eugene Applebaum College of Health Sciences, Wayne State University.

**Degrees/Institutes/Years Earned:**

- BSc, (1<sup>st</sup> Class Hon) Hatfield Polytechnic, University of Hertfordshire, 1976
- PhD, St. Mary's Hospital Medical School, University of London, 1979

**Administrative Accomplishments:** At the University of Texas at Austin: Chair of the



University Research Policies Committee, Chair of the Institutional Animal Care and Use Committee (IACUC), Member - Intellectual Property Committee; Founding Director, Center for Molecular and Cellular Toxicology, College of Pharmacy, University of Texas at Austin, Austin, TX. At the University of Arizona: Professor and Chair, Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona Health Sciences Center; Associate Dean for Research & Graduate Studies, College of Pharmacy, University of Arizona Health Sciences Center; Member – Neuroscience Advisory Council, Associate Deans for Research Council, University Research Development Council. At Wayne State University: Assistant Vice-President for Research – Integrated Biosciences. National: Chairman of Gordon Research Conference on *Drug Metabolism*, Member of several NIH Center for Scientific Review panels, Chairman of Special Emphasis Panel evaluating applications responding to PAR-14-203 “*Environmental Contributors to Autism Spectrum Disorders*”; Academic Program review of several Colleges/Schools of Pharmacy.

**Research Areas:** Ongoing projects include investigations on the acute (hyperthermia) and chronic effects (serotonergic neurotoxicity) of 3,4-(±)-methylenedoxymethamphetamine (MDMA; Ecstasy). Studies with MDMA focus on the role of metabolism in MDMA-mediated serotonergic neurotoxicity, and more recently on the acute, hyperthermic response to MDMA, which is responsible for the vast majority of emergency room admissions and fatalities. The SERT, VMAT-2, and COMT were identified as modulators of the thermoregulatory response to MDMA. Ongoing studies are comparing species differences in thermoregulation, and the significance of such differences when extrapolating experimental findings in rodents to humans. My laboratory is also conducting research on the molecular toxicology of reactive oxygen species (ROS), particularly on the DNA damage stress response and the role of PARP-1. We recently showed that PARP-1 plays opposing roles in the intrinsic and extrinsic pathways to apoptotic cell death, and that the hyperactivation of PARP-1 during the response to DNA damage is reciprocally coupled to elevations in intracellular calcium. Finally, we utilize MS and molecular techniques to identify chemical-protein adducts, and the functional consequences thereof. For example, methylglyoxal-mediated modification of plasminogen has deleterious effects on the fibrinolysis cascade, and may represent a link between T2DM and increased cardiovascular complications.

**ASPET Member Since:** 1986

**ASPET Activities:**

- Editorial Advisory Board, *Drug Metabolism and Disposition* (1986-1997)
- Co-Chair, Symposium “*Estrogen Metabolism and Carcinogenicity*” presented at the ASPET Annual Meeting at EB, Washington, DC (1988)
- Executive Committee, Division for Drug Metabolism (1996-1998)
- Chair-Elect, Division for Toxicology, Program Committee (2002)
- Vice Chair, Division for Toxicology, Program Committee (2003)
- Chair, Symposium “*The Dangers of Designer Drugs*” presented at the ASPET Annual Meeting at EB, San Diego, CA (2003)
- Chair, Division for Toxicology, Program Committee (2004)
- Past-Chair, Division for Toxicology (2005)
- Co-Chair, Symposium “*Genetic Susceptibility to Estrogen Carcinogenesis*” presented at the ASPET Annual Meeting at EB, San Diego, CA (2005)
- ASPET Council (2006-2009)

- Council Liaison, Committee on Graduate Recruitment and Education (2006-2009)
- Long Range Planning Committee (2006-2009)
- Chair, ASPET Awards Committee; Member, Review Committee for ASPET-Astellas Awards in Translational Research (2008-2009)
- FASEB International Issues Subcommittee (2008)

#### **Other Society Memberships/Activities:**

##### Society of Toxicology:

- Chair, Organizing Committee for the Annual Fall Meeting of the Gulf Coast Chapter of SOT, Austin, TX (1990)
- Chair, Symposium “*Quinone Chemistry and Toxicity*” presented at the 30<sup>th</sup> Annual Meeting of the SOT, Dallas, TX (1991)
- Secretary, Gulf Coast Chapter of the SOT (elected) (1992-1993)
- Vice President-Elect, Vice President, President, and Past President, Gulf Coast Chapter of the SOT (1993-1997)
- Vice President-Elect, Vice President, and President, SOT Mechanisms Specialty Section (2000-2003)
- SOT Nominating Committee (elected) (2002)
- SOT Scientific Program Committee (2008-2012)
- Chair, SOT Program Committee, Sponsored Sessions Policy Task Force (2008)

##### American Association of Colleges of Pharmacy (ACCP):

- Academic Research Fellow, “*Leading and Advancing Team Science*” (2013-2014)
- ACCP Research and Graduate Affairs Committee (2014-2016)

## **President-Elect - Edward Morgan**

**Current position:** Professor of Pharmacology, Emory University School of Medicine

#### **Degrees/Institutes/years earned:**

- BSc, (Honours), Pharmacology, University of Glasgow, 1976
- PhD, Pharmacology, University of Glasgow, 1979

#### **Administrative Accomplishments:**

- Administered Emory medical student research program (25-30 students per year) for 8 years and chaired the faculty committee reviewing requests for funding
- Faculty coordinator for move of the Pharmacology department
- Director of Graduate Studies, Biochemistry and Molecular Biology Program for 4 years
- Conceived and co-founded a new interdisciplinary graduate program in Molecular Toxicology and Therapeutics, now called Molecular and Systems Pharmacology (MSP)
- Served as Director of Graduate Studies of MSP program for 3 years and Director for 12 years; chaired program Executive Committee, formulating and administering program policies; recruited program faculty to leadership positions
- Chaired the Executive Committee of the Graduate School of Arts and Sciences

- Chaired the Student Teaching Assignment Committee, Graduate Division of Biological and Biomedical Sciences; Formulated and implemented new guidelines for matching students with appropriate teaching assignments
- Principal Investigator on institutional NIH training grant in the Pharmacological Sciences for 9 years
- Recruited and nucleated 40 faculty from the Schools of Medicine, Public Health and Nursing for submission of an NIEHS P-30 Center grant; ultimately resulting in a P30 Center grant award with Gary Miller as PI
- Chair of the Symposium Committee responsible for the organization of the Emory University-Laney Graduate School Research and Career Symposium (2014-present)

**Research Areas:**

My research interests lie in the regulation of cytochrome P450 enzymes, primarily in the liver. We use animal models of disease to understand the impact of infectious and inflammatory disease on the expression and function of drug metabolizing enzymes. Primary human and rodent hepatocytes are used to address the mechanisms of this regulation. We are currently focusing on the targeted degradation of human P450s by nitric oxide, which is formed by nitric oxide synthase 2 under inflammatory conditions.

**ASPET Member Since:** 1991

**ASPET Activities:**

- Chair, Nominating Committee, Division for Drug Metabolism (1993)
- Chair-Elect, Chair and Past-Chair, Division for Drug Metabolism (1998-2001)
- Program Committee Representative, Division for Drug Metabolism (1998-2001)
- Selection Committee, Bernard Brodie Award (1998)
- Councilor, Division for Drug Metabolism (2003-2006)
- Board of Publications Trustees (2005-2010)
- ASPET Representative, Publications and Communications Committee of FASEB (2006-2009)
- Julius Axelrod Award Committee (2006-2010)
- Executive Committee, Division for Systems and Integrative Pharmacology (2007-2009)
- Secretary/Treasurer-Elect, Secretary/Treasurer and Past Secretary/Treasurer (2011-2014)
- Member Representative, Finance Committee and Investments Subcommittee (2014)
- Editorial Board Member, *Drug Metabolism and Disposition* (1994-2012)
- Associate Editor, *Molecular Pharmacology* (1995-1999)
- Editor-in-Chief, *Drug Metabolism and Disposition* (2012-2018)
- ASPET representative on Advisory Board to the Editor-in-Chief, *FASEB Journal* (2007-2013)
- Bernard B. Brodie Award Committee (2015-2019)
- Organizer, ASPET symposia at ASPET Annual Meeting at EB (1994, 1998, 2001, 2007, 2011, 2016, 2017)

**Other Society Memberships/Activities:**

- International Society for the Study of Xenobiotics (ISSX) Exhibits Committee

(1998-2001)

- ISSX, Scientific Affairs Committee (2008–2012)
- International Union of Basic and Clinical Pharmacology (IUPHAR), Treasurer, Section on Drug Metabolism and Drug Transport, (2014)
- Editorial Board member, *The Biochemical Journal*, The Biochemical Society, (2009-2016)

## Secretary/Treasurer-Elect - Margaret Gnegy

### Degrees/Institutes/Years Earned:

- BS, Chemistry/West Virginia University, 1971
- PhD, Biochemistry, West Virginia University, 1975
- Postdoctoral training, Laboratory of Preclinical Pharmacology, Division of Special Mental Health Research, National Institute of Mental Health, 1975-1977

**Administrative Accomplishments:** Margaret Gnegy, PhD is Professor and Associate Chair for Education in the Department of Pharmacology at the University of Michigan. She has been an ASPET member since 1981 and has been active in ASPET. At the UM, she served as Chair of the Graduate Programs Committee for 20 years and is still serving. Eighteen pre-doctoral trainees and 12 post-doctoral fellows have been trained in her laboratory and she has served as mentor to young UM faculty both within and outside of the Pharmacology Department. From 2005 to 2007 Dr. Gnegy served as the Director of the UM Substance Abuse Research Center and was PI on the NIDA-funded T32 Substance Abuse Interdisciplinary Training Program from 2007 to 2016. Dr. Gnegy has received funding from either NSF or NIH continuously during her career and she served as a member of NSF panels and NIH/CSR study sections. Dr. Gnegy served as a member of the Executive Committee of the NIGMS-funded Pharmacological Sciences Training Program for 20 years and actively contributed to its continuous renewals. In recognition of her exemplary performance in mentoring and training, the UM conferred upon Dr. Gnegy the Rackham Distinguished Graduate Mentor Award for 2009. Recently, she was elected President of the Catecholamine Society (tenure of office, 2016-2018). Dr. Gnegy also serves as an Associate Editor of the journal *Pharmacology & Therapeutics* (2016-2019).

**Research Areas:** The Gnegy laboratory explores the mechanism by which amphetamine interacts with its site of action in eliciting reinforcement, principally the dopamine transporter. The laboratory particularly focuses on the role of signal transduction in altering amphetamine-induced reversal of the dopamine transporter. The results demonstrate that the beta isozyme of protein kinase C (PKC $\beta$ ) enhances amphetamine-stimulated reverse transport of dopamine and also diminishes dopamine D2-type autoreceptor activity. Both effects will increase extracellular dopamine. The laboratory is exploring PKC $\beta$ -modulated interactions between D2 dopamine receptors and the dopamine transporter and ways in which the transporter alters D2 receptor signaling.

Because activation of PKC $\beta$  increases extracellular dopamine, the laboratory has been exploring the action of PKC inhibitors in reducing amphetamine-stimulated locomotor and reinforcing behaviors. As a consequence of these activities, in conjunction with chemists at UM, the laboratory has designed and tested CNS-permeant drugs for inhibition of

amphetamine-stimulated dopamine release and amphetamine-stimulated behaviors. We find that inhibition of PKC $\beta$  reduces amphetamine-stimulated dopamine overflow via microdialysis, amphetamine-stimulated locomotor behavior and amphetamine self-administration.

### **ASPET Member Since: 1981**

#### **ASPET Activities:**

- Membership Committee (1997-2000)
- Chair of Membership Committee (1999-2000)
- Chair, Division for Neuropharmacology (2009-2011)
- Member, Julius Axelrod Award Committee (2011-2015)
- ASPET representative to FASEB Excellence in Science Award Committee (2012-2015)
- Chair, Symposia at ASPET Annual Meeting at EB (1983, 2001, 2012)
- Councilor (2014-2017)
- Member, ASPET Surf Award Task Force (2015-2016)
- Member, ASPET Travel Award Task Force (2016)
- Chair, ASPET Awards Committee (2016-2017)

#### **Other Society Memberships/Activities:**

- American Association for the Advancement of Science
- Society for Neurosciences
- International Society for Neurochemistry
- College on Problems of Drug Dependence
- Catecholamine Society (President, 2016-2018)
- International Transporter Society

### **Secretary/Treasurer-Elect - Michael Jarvis**

#### **Degrees/Institutes/Years Earned:**

- BS and BA, Old Dominion University, 1980
- MS, Old Dominion University, 1982
- PhD, Rutgers University, 1986

#### **Administrative Accomplishments:**

- Increasing levels of research responsibility spanning 30 years of pharma industry experience.
- Led multiple diversified research teams of scientists including molecular biology, electrophysiology, biochemistry, in vivo pharmacology and medicinal chemistry to identify, validate novel drug targets leading to the generation of multiple clinical candidates for pain, inflammation and cardiovascular disease and stroke.
- Currently responsible for scientific/medical oversight for established drugs for the treatment of pain, epilepsy and dyslipidemia

**Research Areas:** Analgesia, Stroke, Cardio-protection, Inflammatory diseases (rheumatoid diseases and osteoarthritis)

**ASPET Member Since:** 1992

**ASPET Activities:**

- Executive Committee, Division for Drug Discovery and Development (2001- present)
- Secretary-Treasurer, Division for Drug Discovery and Development (2005-2007)
- Chair-Elect, Division for Drug Discovery and Development (2007-2009)
- Nominating Committee (2007)
- Chair, Division for Drug Discovery and Development (2009-2011)
- Board of Publication Trustees (2010-2015)
- Web Advisory Committee (2010 – 2013)
- Executive Committee, Division of Translational and Clinical Pharmacology (2013-Present)

**Other Society Memberships/Activities:**

- Member, International Union of Basic and Clinical Pharmacology (IUPHAR)
- Nomenclature Committee-Industrial Consultant, IUPHAR (2005-Present)
- P2X Receptor Sub-Committee, IUPHAR (2009-Present)
- Member, American Heart Association
- Member, BPS
- Member, Society for Neuroscience
- Member, American Pain Society

## Councilor - Susan Ingram

**Degrees/Institutes/Years Earned:**

- AB, Bowdoin College, 1990
- PhD, Oregon Health & Sciences University, 1996

**Administrative Accomplishments:**

I have served as Chair of the ASPET Mentoring and Career Development committee for the past two years (2014-2016). Our long-term goal is to promote a diverse pharmacology workforce who will expand pharmacology as a discipline and contribute to ASPET in the future. I have worked with committee members to organize programming for the EB meeting designed to enhance career skills for young investigators. Our big initiative over the past year has been the ASPET Mentoring Network. I have worked closely with Dr. Lynn Wecker in designing and implementing her ASPET BIG IDEAS I initiative to enhance diversity in ASPET through mentoring. I have also served as Councilor-at-large on the Executive Committee of the ASPET Neuropharmacology Division (2011-2014).

**Research Areas:**

My research is focused on understanding neuronal mechanisms of synaptic plasticity involved

in pain and drug addiction circuits. Our experiments focus on how mu opioid and cannabinoid receptors modulate neuronal excitability and synaptic transmission of neurons in the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM), key areas involved in the descending control of pain. Our recent work has focused on functional selectivity of agonists and specific signaling pathways involved in pre- and postsynaptic GPCR function, as well as the role of adaptations in GABA<sub>A</sub> receptors in the descending pain pathway in morphine tolerance and chronic pain states. Another main area of research in my laboratory is the study of midbrain dopamine neurons in the context of psychostimulant addiction. My lab has shown that amphetamine and methamphetamine potentiate NMDA synaptic signaling in midbrain dopamine neurons through stimulation of the neuronal glutamate transporter EAAT3 trafficking. These effects of amphetamines are dependent on the dopamine transporter and intracellular actions of the psychostimulants and show an important site of integration between dopamine and glutamate signaling pathways. I am interested in understanding the interaction between the limbic system and the descending pain system in chronic pain states.

**ASPET Member Since: 2007****ASPET Activities:**

- Member, Women in Pharmacology Committee (2010-2012)
- Executive Committee, Councilor-at-large, Division for Neuropharmacology (2011-2014)
- Co-Chair, Mentoring and Career Development Committee (2012-2014)
- Chair, Mentoring and Career Development Committee (2014-2016)
- Coach, ASPET Big Idea Mentoring (2016-2017)

**Other Society Memberships/Activities:**

- Organizer, International Narcotics Research Conference (INRC) 2009 meeting (2009)
- Executive Committee Member, INRC (2010-2013)
- Program Committee, INRC (2014-2017)
- Member, Society for Neuroscience
- Member, International Association for the Study of Pain (IASP)

**Councilor - Alan Smrcka****Degrees/Institutes/Years Earned:**

- BS, Biology, University of Connecticut, 1981
- MS, Botany, Arizona State University, 1984
- PhD, Biochemistry, University of Arizona, 1990
- Postdoctoral Fellow, Pharmacology Department, University of Texas Southwestern Medical Center at Dallas, 1990-1994

**Administrative Accomplishments (max 200 words)**

- Molecular Scientific Review Group at the American Heart Association (1998-2001)
- "Pharmacology" study section at NIH (2002-2003)



- “Hypertension Microcirculation” study section at NIH (2003-2006)
- “Molecular and Integrative Signal Transduction (MIST)” study section at NIH (2014-2016)
- Chair, “Molecular and Integrative Signal Transduction (MIST)” study section at NIH (2016-present)

### **Research Areas:**

Our laboratory focuses on mechanisms of signal transduction mediated by G protein-coupled receptors. One major area of research is on analysis of the interactions between the G proteins and their targets at a molecular level with the goals of understanding how these interactions lead to alterations in cellular activities, and to develop novel therapeutic strategies. To this end we have developed antagonists of specific G protein interactions and used these tools to probe investigate G protein functions in physiology and disease. A second major area of work relates to GPCR regulation of cardiac and immune cell functions and disease through subcellular compartmentation of signaling phospholipase C signaling pathways.

**ASPET Member Since:** 1997

### **ASPET Activities:**

- Chair, Division for Molecular Pharmacology (2009-2010)
- Editorial Board, *Molecular Pharmacology* (2012-2016)
- Associate Editor, *Molecular Pharmacology* (2016-present)
- Editorial Board, *Pharmacological Reviews* (2016-present)

### **Other Society Memberships/Activities:**

- American Association for the Advancement of Science
- American Society of Biochemistry and Molecular Biology

### **Councilor - Michael Wood**

#### **Degrees/Institutes/Years Earned:**

- BS, Environmental Health, Oakland University, 1992
- PhD, Duke University, 1996

#### **Administrative Accomplishments:**

Within AstraZeneca Pharmaceuticals, I worked as a Licensing and Collaboration Director (2011-2016) during which I forged and led key academic collaborations (e.g., A5, VCNDD), administrated over numerous licensing evaluations (e.g., AZD1858), and directed pharmacology expertise on multiple due diligence missions. Before that, I was the Psychiatry Target Team Leader and was responsible for identification/validation, launch and shepherding to lead optimization all projects within the psychiatry portfolio (e.g., AZD4451). Within AZ, I



have also been a line manager of a team of up to 10 direct reports responsible for developing molecular reagents into feasible assays. I recently founded Neupharm LLC, a drug discovery consulting company.

**Research Areas:**

My scientific research has been focused on applying pharmacology to the identification of new treatments for diseases of the nervous system. Throughout my career, I have contributed substantively to dozens of drug discovery projects at various stages of maturation. Early on, my efforts in drug hunting research focused on psychiatric indications (see the Albert/Wood book Targets and Emerging Therapies for Schizophrenia). Later, my focus expanded to include identifying novel treatments for pain and neurodegenerative disease. Recently, I co-led the A5 collaboration which included renown Alzheimer's researchers from four academic institutions. Efforts on two novel drug targets from this collaboration are still continuing. The driving force in my research experience has been application of the principles of pharmacology to advance programs seeking to treat patients suffering nervous system disorders who are not served by the current formulary.

**ASPET Member Since:** 2010

**ASPET Activities:**

- Program Committee Representative, Division for Neuropharmacology (2010-2014)
- Member-at-Large, Program Committee, Division for Neuropharmacology (2014-2017)
- Secretary/Treasurer, Division for Neuropharmacology (2015-2017)

**Other Society Memberships/Activities:**

- Symposium Organizer, "*Multi-Target Agents: The Yin and Yang of Rational Drug Discovery*" (2012)
- Symposium Organizer, "*Apolipoprotein E: A Protein at the Intersection of Vascular and Neurodegenerative Disease Biology*" (2013)
- Colloquium Organizer, "*Drug Discovery in Academia: Recent Success and Emerging Opportunities*" (2016)

**Division for Behavioral Pharmacology Chair-Elect - Jun-Xi Li****Degrees/Institutes/Years Earned:**

- MD, Binzhou Medical University, 2000
- PhD, Peking University, 2005

**Administrative Accomplishments:**

I have been serving as a councilor on the Division for Behavioral Pharmacology of ASPET for three years. During this period, I learned the nuances of running and organizing scientific programs and activities. This experience will be invaluable for me to potentially serve the Division in the future to continue and expand the annual meeting-related businesses and

scientific activities. I participated in organizing the 2016 New York Pharmacology Society (a chapter of ASPET) annual meeting in May, which was a successful event.

**Research Areas:**

My primary research interests are the behavioral pharmacology of pain and drug abuse. For pain-related research, I have been investigating the potential of imidazoline I<sub>2</sub> receptor ligands and subtype-selective GABA<sub>A</sub> receptor positive modulators for the treatment of chronic pain. For drug abuse-related research, I have been active in deciphering the role of central trace amine-associated receptor 1 in mediating psychostimulant addiction. The long term goals for both lines of research are to develop novel target-based pharmacotherapies to treat pain and addiction.

**ASPET Member Since:** 2007**ASPET Activities:**

- Councilor, Division for Behavioral Pharmacology (2013 - 2016)
- President-Elect, New York Pharmacology Society/ASPET Chapter (2016)

**Other Society Memberships/Activities:**

- Member, College on Problems of Drug Dependence
- Member, Publications Committee, College on Problems of Drug Dependence
- Member, Society for Neuroscience

**Division for Behavioral Pharmacology Secretary/Treasurer-Elect - Gregory Collins****Degrees/Institutes/Years Earned:**

- BA, Biology with minors in Chemistry and Philosophy, University of St. Thomas, 1999
- PhD, Pharmacology, University of Michigan Medical School, 2008

**Administrative Accomplishments:**

In addition to my research efforts, I have been active in a variety of administrative duties, including a two-year term as the post-doctoral representative to the Executive Committee of the Division for Behavioral Pharmacology at ASPET, and a four-year term as a member of the Institutional Animal Care and Use Committee (IACUC) of the South Texas Veterans Health Care System. As a post-doctoral representative of the BPD, I participated in all teleconferenced and in person meetings of the executive committee where I represented the interests of the graduate students and post-doctoral members of the division. During this time I also participated in the development of the Behavioral Pharmacology Division's scientific program for the ASPET Annual Meetings at EB. As a member of the IACUC at the South Texas Veterans Health Care System, I am responsible for ensuring that all animal use protocols, VA research laboratories comply with the ethical standards set forth by the Guide for the Care and Use of Laboratory Animals.

**Research Areas:**

My longstanding research interests are to understand the determinants of drug and conditioned reinforcement with the ultimate goal of developing effective behavioral and pharmacological treatments to reduce drug use and help individuals remain abstinent. Accordingly, I utilize intravenous self-administration procedures in rats and monkeys to assess the degree to which factors such as age, diet, sex, and drug history influence (1) the acquisition of drug-taking, (2) the reinforcing effectiveness of drugs, and (3) the effectiveness of drug-associated stimuli to promote/maintain responding during periods in which the drug is no longer available. Current research in my laboratory is focused on characterizing the abuse-related and toxic effects of synthetic cathinones (e.g., MDPV and methylone), an emerging class of abused drugs commonly referred to as “bath salts”. Through the use of quantitative approaches, these studies are aimed at determining whether the discriminative stimulus, reinforcing and cardiovascular effects of synthetic cathinones are altered when they are administered in combination with other common “bath salts” constituents, such as another cathinone, or caffeine.

**ASPET Member Since:** 2005

**ASPET Activities:**

- Post-Doctoral Representative, Division for Behavioral Pharmacology (2009-2011)
- Volunteer, ASPET Day of Service(2009, 2010, 2012, 2015, 2016)
- Symposium Organizer/Chair/Participant, Division for Behavioral Pharmacology, “*Pharmacokinetic approaches to the treatment of drug abuse*” presented at the ASPET Annual Meeting at EB, Washington, DC (2011)
- Poster Judge, Division for Behavioral Pharmacology(2013 - 2016)
- Ad hoc Reviewer, *Journal of Pharmacology and Experimental Therapeutics*
- Laboratory Mentor, ASPET SURF program (2013, 2014)
- Symposium Participant, Behavioral Pharmacology Division, “*Quantitative Pharmacological Analysis of In Vivo Data and Its Implications in CNS Drug Discovery*” presented at the ASPET Annual Meeting at EB, San Diego, CA (2016)

**Other Society Memberships/Activities:**

- Behavioral Pharmacology Society
- College on the Problems of Drug Dependence
- International Study Group Investigating Drugs As Reinforcers
- Society for Neuroscience
- Young Investigator Memorial Travel Award , American College of Neuropsychopharmacology (2013)

## Division for Behavioral Pharmacology Secretary/Treasurer-Elect - Susan Wood

### Degrees/Institutes/Years Earned

- BS, University of Michigan , 2001
- PhD, University of Michigan , 2006

### Administrative Accomplishments:

I have attended the ASPET Annual Meeting at Experimental Biology since graduate school and know first-hand the incredible opportunities that are afforded to members of this Society. I served on ASPET's Division for Behavioral Pharmacology Executive Committee as a postdoctoral representative, gaining valuable insight into the critical inner workings of these Divisional Committees. I am also involved in the American Physiological Society (APS) and served on the Executive Committee of Water and Electrolyte Homeostasis Division's Postdoctoral Trainee Advisory Committee, where we developed and launched a "mentoring on the go" program that paired graduate students and postdocs with a mentor to discuss science, careers, etc. This program is a huge success and encourages students to expand their scientific network. Since becoming a Tenure-Track Assistant Professor I encourage my students to attend ASPET, of which they have been awarded poster presentation and travel awards. I also greatly enjoy contributing to the Society by serving as a poster judge. Beyond my dedication to ASPET, I have confidence that I could serve as an exceptional secretary/treasurer given my experience managing large budgets, from start-up funds to NIH grants. Furthermore, I have significant leadership experience; from managing 7 members of my laboratory, to serving as director and co-director for two graduate level courses.

### Research Areas:

Approximately 1 in 6 American's develop stress-related psychiatric disorders, including depression and anxiety. However, there is evidence to suggest that traditional antidepressant/anxiolytic therapies only moderately reduce symptoms, achieving only 30% remission. The focus of my research program is to elucidate novel biomarkers and pharmacological targets to more effectively treat stress-induced pathologies. We utilize a model of social defeat stress that recapitulates the individual differences in stress susceptibility that is evident in people. This allows us to identify endogenous mechanisms of resiliency and vulnerability, thereby providing targets to either enhance or antagonize, respectively.

Furthermore, females are twice as likely to suffer from these stress-related disorders (for example, depression and post-traumatic stress disorder). Therefore, ongoing work in my lab also utilizes a rodent model of witness stress in females that produces relevant anxiety- and depressive-like endpoints, thereby allowing for the identification of novel targets selectively in the female population. A third major focus in my lab expands upon the knowledge that psychopathology increases the risk of cardiac morbidity by 2-3 fold. We therefore have studies aimed at elucidating putative mechanisms involved in the pathogenesis of this comorbidity with the hopes of identifying therapeutics effective in treating both the mind and the heart.

**ASPET Member Since:** 2005

**ASPET Activities:**

- Graduate Student Travel Award, (2006)
- Graduate Student Best Abstract Award, ASPET (2006)
- Postdoc Representative, Executive Committee, Division for Behavioral Pharmacology (2007-2009)
- Young Scientist Travel Award (2008, 2009)
- Postdoctoral Scientist Award, 1st place, Division for Behavioral Pharmacology (2008)
- Postdoctoral Scientist Award, 2nd place, Division for Behavioral Pharmacology (2010)
- Poster Judge, Best abstract award competition, Division for Behavioral Pharmacology (2013 - Present)
- Nominated by Editor and Chief of JPET, Dr. Kenneth Tew, to serve on the Editorial Board, *Journal of Pharmacology and Experimental Therapeutics* (pending)

**Other Society Memberships/Activities:**

- Member, Society for Neuroscience (SFN) (2007 - Present)
- Postdoctoral Poster Award, 1st place, Philadelphia Chapter of the SFN (2009)
- Member, Behavioral Pharmacology Society (2008 - Present)
- Member, European Behavioral Pharmacology Society (2009 - Present)
- Postdoctoral Bursary Award, European Behavioral Pharmacology Society (2009)
- Member, American Physiological Society (APS) (2009 - Present)
- Member, APS Water and Electrolyte Division
- Trainee Advisory Committee, APS Water and Electrolyte Homeostasis (2010 - 2013)
- Co-founder, "Mentoring on the Go" mentoring program, APS Water and Electrolyte Division (2013)
- Abstracts Judge, "Data Diuresis" finalists (2014)
- Member, American Heart Association (2010 - Present)

**Division for Cardiovascular Pharmacology Chair-Elect - David Busija****Degrees/Institutes/Years Earned:**

- BS, University of Pittsburgh, 1972
- MA, University of Kansas, 1974
- PhD, University of Kansas, 1978
- *Doctorem Medicinae Honoris Causa* (MD (Hon)), University of Szeged, 2009 (awarded for sustained contributions to the University of Szeged, Hungary since 1995)

**Administrative Accomplishments:**

As chair of the ASPET Division for Cardiovascular Pharmacology, I will: 1) continue successful policies which have widespread support, 2) initiate policies to accelerated integration of information into the EB program, 3) foster greater communication within the membership, and 4) develop strategies for inclusion of our diverse membership in decision making processes. I will draw upon my 30 years of scientific and financial experience administering a successful NIH funded research program, the administrative and financial experience as Chair of the Department of Pharmacology at Tulane University School of Medicine, and my sustained,

professional service to ASPET and APS. I am currently a member of the Executive Committee of the ASPET Division for Pharmacology Education as well as Treasurer of the Association of Medical School Pharmacology Chairs. I bring experience to this ASPET committee from serving on the APS Cardiovascular Section in numerous capacities. Current challenges for the success of the Cardiovascular Section include the general economic and NIH funding crises, the coupling of EB programing with the rapid advances in cardiovascular sciences, and the dynamic demographic characteristics of our membership.

**Research Areas:**

My research is represented by almost 300 publications in the cardiovascular field as well as continuous NIH grant funding since 1982. I have trained 35 graduate students and postdoctoral fellows. My research is focused on: 1) Mechanisms involved in the regulation of the cerebral circulation in health and disease, 2) Mechanisms of damage to the brain following injury, and 3) Therapeutic strategies to protect the cerebral vasculature and brain during disease processes such as metabolic syndrome and ischemia/reperfusion. These seemingly unrelated topics are unified by the focus on the role of mitochondria. Activation of mitochondria promotes dilation of cerebral arteries by mechanisms involving increases in calcium sparks activity by smooth muscle as well as production and actions on smooth muscle of nitric oxide produced by endothelium and neurons. Targeting mitochondria with activators of ATP sensitive potassium channels on the inner mitochondrial membrane protects cells by reducing increases in the production of reactive oxygen species following exposure to lethal stimuli. The metabolic syndrome reduces dilation to mitochondrial activators and impairs mitochondrial mediated protection as a result of local inflammatory processes and increased cellular and tissue levels of reactive oxygen species. Current studies are examining ischemic effects on mitochondrial dynamics in cerebral arteries and brain.

**ASPET Member Since:** 2010**ASPET Activities:**

- Member of ASPET Cardiovascular Division
- Attended and participated in every ASPET Annual Meeting at Experimental Biology since 1978
- Joint Program Committee, ASPET/APS Annual Meeting at Experimental Biology
- Member of ASPET Cardiovascular Division Awards Committee
- APS Liaison to ASPET Division for Pharmacology Education
- Executive Committee of ASPET Division for Pharmacology Education
- Reviewer of ASPET Summer Undergraduate Research Fellowship (SURF) Awards

**Other Society Memberships/Activities:**

- Treasurer, Association of Medical School Pharmacology Chairs (AMSPC)
- Organizer, AMSPC mixers at ASPET Annual Meeting at Experimental Biology
- Cardiovascular Section Representative, American Physiological Society (APS)
- APS Advisor, International Union of Physiological Society Program Committee
- Training Committee, Cardiovascular Section, APS

- Committee on Committees, APS
- Steering Committee Member, Cardiovascular Section, APS

## **Division for Cardiovascular Pharmacology Chair-Elect - Fadi Khasawneh**

### **Degrees/Institutes/Years Earned:**

- BPharm, Jordan University of Science and Technology, Jordan, 1999
- PhD, Pharmacology, University of Illinois at Chicago, 2007

### **Administrative Accomplishments:**

- Chair, Academic Senate at Western University (2013-2015)
- Secretary/Treasurer, ASPET Division for Cardiovascular Pharmacology (2014-2016)
- Chair, Biological Sciences Section of the American Association of Colleges of Pharmacy (2015-2016)

### **Research Areas:**

Dr. Khasawneh's research program is focused on Cardiovascular Disease; specifically in the area of thrombogenesis and platelet signaling. He is interested in characterizing the structural biology of the various G-protein Coupled Receptors, the role of the transient receptor potential channel 6, as well as the role of the regulators of G-Protein signaling, in platelet activation and thrombotic disorders. Another goal is to map the G-protein coupling domains of certain platelet G-protein coupled receptors. We are also interested in repurposing old drugs (FDA-approved) for new use (Drug Rediscovery). Our ultimate goal is to identify novel therapeutic targets for the management of thromboembolic disorders. Ultimately, these studies should define new agents and/or targets for managing thromboembolic disease states.

**ASPET Member Since:** 2006

### **ASPET Activities:**

- Primary Member, Division for Cardiovascular Pharmacology (2006-present)
- Co-Chair, Junior Scientists' Competition, Division for Cardiovascular Pharmacology, ASPET Annual Meeting at EB, San Diego, CA (2008)
- Member, Division for Cardiovascular Pharmacology's Competition Committee (2009-present)
- Member, Division for Cardiovascular Pharmacology Executive Committee (2010-present)
- Chair, Division for Cardiovascular Pharmacology's Trainee Showcase Symposium Committee (2010-2011)
- Judge, ASPET Student/Postdoctoral Best Abstract Competition (2012-2016)
- Secretary/Treasurer, Division for Cardiovascular Pharmacology (2014-2016)
- Chair, Division for Cardiovascular Pharmacology's Program Committee (2014-2016)
- Member, Program Committee (2014-2016)
- Member, Nominating Committee (2014 and 2016)
- Reviewer, *Molecular Pharmacology*



**Other Society Memberships/Activities:**

- Member, The Honor Society of Phi Kappa Phi (2005-present)
- Member, The Scientific Research Society, Sigma Xi (2005-present)
- Member, The American Heart Association (2005-present)
- Member, American Association of Colleges of Pharmacy (2009-present)
- Member, The American Society of Hematology (2009-present)
- Member, Kappa Psi Pharmaceutical Fraternity (2010-present)
- Member, The Rho Chi Society (2013-present)
- Chair, Faculty Orientation and Development Committee, College of Pharmacy, Western University of Health Sciences (2016-present)
- Chair, Research Committee, Western University of Health Sciences (2015-2016)
- Vice Chair, Institutional Animal Care and Use Committee (IACUC), Western University of Health Sciences (2015-2016)
- Chair, Academic Senate, Western University of Health Sciences (2013-2015)
- Co-Chair, Thrombosis Basic 1 Peer Review Committee, The American Heart Association (2015-2016)
- Member, Hematology VA Merit Review Committee, Veterans Health Administration (2015-present)
- Member, Innovative Research Grant (IRG) Vascular Regulation & Disease 2 Peer Review Committee, The American Heart Association (2016-present)

**Division for Cardiovascular Pharmacology Chair-Elect - Hemal Patel****Degrees/Institutes/Years Earned:**

- BS, Biology, Truman State University, 1998
- BA, Philosophy & Religion, Truman State University, 1998
- PhD, Pharmacology & Toxicology, Medical College of Wisconsin, 2002

**Administrative Accomplishments:**

I have applied my leadership skills to organizing and developing groups at multiple levels. I have been Director of Laboratories of the UCSD Cardio-Neuro Protection Group, comprised of four laboratories, since 2006. The group coordinates a highly interdisciplinary environment to better understand the impact of caveolin in disease. The group has produced a successful training environment for many and significant active funding (i.e., NIH, VA, NASA, DoD, and various foundations). In 2015, I was appointed Vice-Chair for Research in the Department of Anesthesiology. I undertook oversight of basic and clinical research efforts for the Department. My office is in charge of research retreats, the research advisory group to evaluate internal proposals, the T32 research training program, and faculty scholarly travel. In addition, I have served as the Chair of the Veterans Administration Hospital IACUC since 2009 overseeing the animal research program, as well as served as Chair of the UCSD School of Medicine Admissions Committee since 2014. Outside of the institution, I have served as Chair of a study section for the AHA since 2014. These multiple leadership positions, in very diverse capacities, have taught me well how to manage people with diverse opinions to move common goals forward.



**Research Areas:**

My research interests relate to how membrane microdomains (i.e., lipid rafts and caveolae) transmit signals to intracellular organelles (i.e., mitochondria, endoplasmic reticulum, and nucleus) as a means to regulate cell and organ physiology. I utilize molecular, cellular, organ and whole animal based models to approach a variety of scientific problems. We are assessing a variety of therapeutic approaches that intervene at the level of caveolin to modulate cardiovascular disease, diabetes, cancer, neurodegeneration, vascular regulation, and renal biology.

**ASPET Member Since:** 2005

**ASPET Activities:**

- Executive Committee Member, Division for Cardiovascular Pharmacology (2006-present)
- Chair, Membership Committee, Division for Cardiovascular Pharmacology (2009)
- Co-Chair, Competition Committee, Division for Cardiovascular Pharmacology (2010-2012)
- Chair, Competition Committee, Division for Cardiovascular Pharmacology (2013-present)

**Other Society Memberships/Activities:**

- Member and Co-Chair, Cell transport peer review group, American Heart Association, (2012-2013)
- Chair, Cell transport peer review group, American Heart Association (2014-present)
- Member of Fellowship/Membership Committee, American Physiological Society, Cardiovascular Section (2011-2014)
- Member of Marcus Award Committee (2014-present)

**Division for Cardiovascular Pharmacology Secretary/Treasurer-Elect - Amy Arnold****Degrees/Institutes/Years Earned:**

- BS, Biochemistry, Pacific University, 2004
- PhD, Physiology and Pharmacology, Wake Forest University, 2009
- MS, Clinical Investigation, Vanderbilt University, 2014

**Administrative Accomplishments:**

I have a long history of service to my institution and to scientific societies including ASPET, American Heart Association, American Physiological Society, and American Autonomic Society. I am an ad hoc reviewer for over 20 journals and currently serve on editorial boards for *Physiological Genomics* and the *American Journal of Hypertension*.

**Research Areas:**

My research examines the role of the renin-angiotensin system in the neural control of blood pressure and metabolism. Current studies focus on mechanisms by which angiotensin-(1-7) improves blood pressure and insulin sensitivity in cardiometabolic diseases including obesity and hypertension. These studies utilize a variety of approaches in mice including in vivo cardiovascular monitoring, pharmacologic and spectral analysis of autonomic function, and measurement of insulin action. We also have translational studies examining effects of systemic angiotensin-(1-7) infusion on blood pressure and insulin sensitivity in patients with essential hypertension.

**ASPET Member Since:** 2007

**ASPET Activities:**

- Executive Committee, Division for Cardiovascular Pharmacology (2009-present)
- Long Range Planning Committee (2011)
- Reviewer, Summer Undergraduate Research Fellow Awards (2013-2014)
- Executive Committee, Division for Pharmacology Education (2013-2016)

**Other Society Memberships/Activities:**

- Trainee Advisory Committee, American Physiological Society (2009-2012)
- Awards Committee, American Physiological Society (2013-2016)
- Membership Committee, American Autonomic Society (2013-present)
- Council on Hypertension Trainee Advocacy Committee, American Heart Association (2016-present)

**Division for Cardiovascular Pharmacology Secretary/Treasurer-Elect -  
Anastasios Lymperopoulos**

**Degrees/Institutes/Years Earned:**

- BSc, Pharmacy, University of Patras, Greece, 1998
- MSc, Medicinal Chemistry, University of Patras, Greece, 2000
- PhD, Pharmacology, University of Patras, Greece, 2004
- Post-Doctoral Fellowship, Cardiovascular Biology, Thomas Jefferson University, 2004-2009

**Administrative Accomplishments:**

- Former Jefferson Post-Doctoral Association (JPA) Executive Board Member, Thomas Jefferson University (2006-2009)
- Former Research Committee Chair, NSU College of Pharmacy, Nova Southeastern University (2009-2015)

**Research Areas:**

Molecular pharmacology and physiology of cardiovascular G protein-coupled receptors (GPCRs). More specifically, I study signal transduction mechanisms of cardiac adrenergic and

angiotensin receptors in heart failure (HF) pathophysiology and the roles of adrenal GPCRs in regulation of circulating levels of catecholamines and of aldosterone in HF. Particular focus is given on GRKs and beta-arrestins, two protein families that regulate GPCR signaling/function in the heart & adrenals, in HF pathophysiology. The main goal of my research is to validate certain GRK and arrestin family members as therapeutic targets for heart disease.

**ASPET Member Since:** 2015

**ASPET Activities:**

- Chief organizer, Chair & Speaker at ASPET's Division for Drug Discovery and Development-sponsored symposium entitled: "*Targeting of GRKs and Beta-arrestins for Cardiovascular Therapy: Picking on Certain Siblings over Others in Some (Protein) Families*", part of the scientific program at the ASPET Annual Meeting at EB2017 in Chicago, IL (2017)

**Other Society Memberships/Activities:**

- Fellow, European Society of Cardiology (FESC)
- Fellow, American Heart Association (FAHA)
- Former American Heart Association's Scientist Development Grant (SDG) & Post-Doctoral Fellowship Awardee
- Former American Heart Association's Melvin L. Marcus Young Investigator Award in Cardiovascular Sciences Finalist (2006)
- Former Cardiovascular Research Award in Basic Cardiovascular Sciences of the European Society of Cardiology Finalist (2010)
- Grant Reviewer, American Heart Association (AHA) & American Association of Colleges of Pharmacy (AACP)

## **Division for Cardiovascular Pharmacology Secretary/Treasurer-Elect - Douglas Tilley**

**Degrees/Institutes/Years Earned:**

- BScH, Queen's University at Kingston, Ontario, Canada, 1999
- PhD, Queen's University at Kingston, Ontario, Canada, 2005

**Administrative Accomplishments:**

In terms of administrative accomplishments and service, I have participated in various endeavors at the institutional, regional and national levels. At Temple University, I have been a member of the Graduate Studies Committee and I am currently a member of the Dean's Research Committee, Small Animal User Committee, Basic Science Faculty Effort Advisory Committee, and the Liaison Committee for Medical Education (LCME) Steering Committee. Regionally, I have been a member of the Mid-Atlantic Pharmacology Society (MAPS; a local chapter of ASPET) for a number of years and I am currently serving as President. In this capacity, I was able to introduce a travel award to enable MAPS trainees to attend the ASPET Annual Meeting at Experimental Biology. Nationally, I have participated on a number of

American Heart Association (AHA) committees and reviewed AHA grant applications for several years. More recently, I was invited to participate for back-to-back cycles as an Ad Hoc member of the Cardiac Contractility and Heart Failure Study Section at the NIH. Throughout these activities, I have also offered my services as a reviewer for numerous journals and have recently joined the editorial board of *Cellular Signaling*.

**Research Areas:**

During heart failure, alterations in cardiomyocyte receptor signaling mediate changes in hypertrophy, survival and contractile function that contribute to the progression of the disease. G protein-coupled receptors (GPCR) relay signals via both G protein-dependent and -independent mechanisms, which include 2nd messenger generation and GPCR kinase (GRK)/ $\beta$ -arrestin signaling, respectively. My research focuses on three aspects of receptor regulation of cardiac function, inflammation and remodeling during heart failure (HF) or following acute cardiac injury. First, we are developing a next generation approach to  $\beta$ AR-targeted therapeutics to harness biased activation of cardioprotective  $\beta$ AR signaling in the absence of cardiotoxic pathways, specifically exploring the impact of  $\beta$ AR-mediated epidermal growth factor receptor (EGFR) transactivation on cardiac function and survival under HF conditions. Second, we are elucidating the impact of arginine vasopressin (AVP) type 1A receptor (V1AR) signaling on  $\beta$ AR responsiveness, cardiac function and remodeling following acute injury. Third, since  $\beta$ 2AR are expressed on virtually all cells of hematopoietic origin, we are investigating the impact of immune cell-specific  $\beta$ 2AR signaling, via both G protein- and  $\beta$ arr-dependent mechanisms, on the inflammatory and reparative processes following acute cardiac injury.

**ASPET Member Since:** 2008**ASPET Activities:**

- Poster Judge, Division for Molecular Pharmacology, ASPET Annual Meeting at Experimental Biology (intermittently from 2009-present)
- President, Mid-Atlantic Pharmacology Society (MAPS), a local chapter of ASPET (2014-present)

**Other Society Memberships/Activities:**

- Professional Member, American Heart Association (AHA) (2011-present)
- Grant reviewer, AHA Molecular Signaling Basic Science 1 (2012-2015)
- Member, AHA Membership & Communications Committee of the Basic Cardiovascular Sciences (BCVS) Council (2014-present)
- Grant Reviewer, Natural Sciences and Engineering Research Council (NSERC) of Canada, Discovery Grants Program (2015)
- Member, AHA Committee on Scientific Sessions Program (2015-2016)
- Ad-hoc Reviewer, Cardiac Contractility, Hypertrophy and Failure Study Section Center for Scientific Review, NIH (February and June meetings, 2016)
- Editorial Board Member, *Cellular Signaling* (2016-2018)
- Member, BCVS Scientific & Clinical Education Lifelong Learning (SCILL) Committee of the AHA (2016-2019)

## Division for Drug Discovery and Development Chair-Elect - Craig Beeson

### Degrees/Institutes/Years Earned:

- BS, California State University, Northridge, 1982
- MS, San Diego State University, CA, 1985
- PhD, University California, Irvine, 1993

### Administrative Accomplishments:

Dr. Beeson is the Core Director of the MUSC/Seahorse Biosciences Academic Facility and the Redox COBRE Metabolomics Core. He has pioneered the assessment of cellular bioenergetic functions as they relate to disease pathologies.

### Research Areas:

Dr. Beeson is a physical organic chemist with postdoctoral training in biophysics. Research in the Beeson lab is focused on signal transduction pathways for cellular stress responses that are integrated with bioenergetic metabolism and mitochondrial physiology. He has translated these studies to the development of high-throughput drug screening strategies that have led to drug leads for the treatment of retinal dystrophies and neurodegenerative pathologies. Dr. Beeson developed one of the first "microphysiometers" with the capability to measure cellular respiration and was part of the design team that consulted with Seahorse Biosciences in the development of XF technology – the first production XF instrument was placed in his lab at MUSC and he published some of the first studies using XF technology.

**ASPET Member Since:** 2004

### ASPET Activities:

- Editorial Board, *Journal of Pharmacology and Experimental Therapeutics* (2004-2009)
- Secretary/Treasurer, Division for Drug Discovery and Development (2015-2017)
- Nominating Committee (2016-2017)

### Other Society Memberships/Activities:

- Member, American Chemical Society

## Division for Drug Discovery and Development Secretary/Treasurer-Elect - Alvin Terry, Jr.

### Degrees/Institutes/Years Earned:

- AS, Pre-Pharmacy, North Greenville College, 1979
- BS, Pharmacy, Medical University of South Carolina, 1982
- PhD, Pharmacology, University of South Carolina, 1991

### Administrative Accomplishments:

In 1999, Dr. Terry served as the first director of a graduate program at the University of Georgia (UGA), College of Pharmacy, known as the UGA Clinical and Experimental Therapeutics (CET) Program. While similar to a pharmacology PhD program, the CET program offers unique (translational) components such as clinical rotation requirements, courses on clinical trials and regulatory rules, and it capitalizes on the unique basic science and clinical training of pharmacy school faculty. Later, in 2003, at the Medical College of Georgia (now part of Augusta University), Dr. Terry created an institutional research core, the Small Animal Behavior Core (SABC), which is a state-of-the-art facility designed to serve as a time-efficient and cost-effective service for researchers in need of behavioral analyses in small animals. In February, 2014 Dr. Terry became the Chair of the Department of Pharmacology and Toxicology at AU and in July, 2015, he was appointed as the Inaugural Associate Vice President for Basic Science Research at AU. In this role, he has administrative oversight over the Division of Laboratory Animal Services (DLAS) and works closely with the Senior Vice President for Research to oversee and manage multiple aspects of the university's basic science research mission.

### **Research Areas:**

Dr. Terry's research interests focus on the role of central acetylcholine (i.e., cholinergic) pathways in cognition; specifically how these neuronal pathways are involved in the memory dysfunction associated with neuropsychiatric illnesses and exposures to environmental toxins, especially organophosphates. The actions of both pharmaceutical and toxicological agents on the cholinergic neuronal system, axonal transport, as well as the major growth factors (nerve growth factor, brain derived growth factor) that support the cholinergic system are of particular interest. His laboratory also focuses on drug discovery and development strategies for the treatment of disorders of cognition. The laboratory employs a variety of methods to test hypotheses ranging from behavioral testing in animal models (rodents to non-human primates) to molecular, cellular and analytical techniques. To date, Dr. Terry has published 153 peer-reviewed research articles, 8 book chapters, and holds 1 US patent. His research is currently supported by the National Institutes of Health (NIH), the Department of Defense (DOD), and the pharmaceutical industry.

### **ASPET Member Since: 2000**

#### **ASPET Activities:**

- Editorial Advisory Board, *Journal for Pharmacology and Experimental Therapeutics*
- Member, Division for Drug Discovery and Development

#### **Other Society Memberships/Activities:**

- Society for Neuroscience
- Society of Toxicology

## Division for Drug Metabolism Chair-Elect - Xinxin Ding

### Degrees/Institutes/Years Earned:

- BS, Biology, Nanjing University, 1982
- PhD, Biological Chemistry, University of Michigan, 1988

### Administrative Accomplishments:

- Director, Toxicology Track, Department of Environmental Health Sciences, School of Public Health, SUNY at Albany (2000-2014)
- Chief, Laboratory of Molecular Toxicology, Division of Environmental Health Sciences, Wadsworth Center, NYSDOH (2007–2014)
- Treasurer, Local Organizing Committee for the 17<sup>th</sup> International Symposium on Microsomes and Drug Oxidations, Saratoga Springs, NY (2008)
- Chair, Program Committee for the 18<sup>th</sup> International Symposium on Microsomes and Drug Oxidations, Beijing, China (2010)
- Director, Center for Preclinical Nano-Drug Discovery and Development, CNSE, SUNY Polytechnic Institute (2014–present)
- Chair, NIH Xenobiotic and Nutrient Disposition and Action (XNDA) Study Section (2016-present)

### Research Areas:

Current studies are focused on the function and regulation of microsomal cytochrome P450 enzymes in various organ systems. The P450 enzymes metabolize numerous drugs, chemical carcinogens, environmental pollutants, as well as endogenous signaling molecules. A major area of research involves development and application of genetically engineered mouse models for functional studies. A series of novel mouse models with tissue-selective deletion or down-regulation of the P450 reductase gene, as well as mouse models that have selected mouse P450 genes deleted, and/or express human P450 enzymes, have been produced. These animals are being used to model human genetic deficiency, and to explore the role of P450 enzymes in drug disposition, response, and toxicity. Complementary to studies in animal models, we are also studying expression and genetic polymorphisms of human P450 and P450 reductase genes, in order to identify the genetic basis for inter-individual differences in clinical response to drug therapy, and to predict the cancer risks of exposure to commonly occurring environmental chemicals. Furthermore, we are initiating basic as well as preclinical studies on the pharmacology of nano-drugs that are designed to improve therapeutic efficacy and safety profile, or to provide better protection against environmental diseases.

**ASPET Member Since:** 1997

### ASPET Activities:

- Member, Nominating Committee, Division for Drug Metabolism (2000-2004)
- Councilor, Division for Drug Metabolism (2001-2004)
- Member, Best Paper Selection Committee, Division for Drug Metabolism (2001-2003, 2005)
- Member, Executive Committee, Division for Drug Metabolism (2001-2007)

- Secretary/Treasurer, Division for Drug Metabolism (2005-2006)
- Member, Nominating Committee (2005-2006)
- Associate Editor, *Drug Metabolism and Disposition* (2010-2018)

**Other Society Memberships/Activities:**

- Member, American Society for Biochemistry and Molecular Biology (ASBMB) (1988-present)
- Member, International Society for the Study of Xenobiotics (ISSX) (1993-present)
- Member, Society of Toxicology (1995-present)
- Member, Student Award Committee, Society of Toxicology, Molecular Biology Specialty Section (2002, 2003)
- Member, American Association for Cancer Research (2004-present)
- Member, Chemistry in Cancer Research Working Group's Young Chemists Committee, American Association for Cancer Research (2006-2008)
- Member, Program Committee, 15<sup>th</sup> North American ISSX Meeting (2008)
- Member, Editorial Board, *Journal of Biological Chemistry*, ASBMB (2009-2014)
- Member, Scientific Advisory Board for the 10<sup>th</sup> International ISSX meeting (2013)

**Division for Drug Metabolism Chair-Elect - Aiming Yu****Degrees/Institutes/Years Earned:**

- BS, Central China Normal University, Wuhan, China, 1993
- PhD, Nankai University, Tianjin, China, 1998

**Administrative Accomplishments:**

- Member, PTX Graduate Admission Committee, UC Davis (2013-2016)
- Director, PK/PD Bioanalytical Core Facility, UC Davis (2013–present)
- Member, Executive Committee, PTX Graduate Group, UC Davis (2016-present)
- Co-Chair, PTX Graduate Admission Committee, UC Davis (2016)

**Research Areas:**

Dr. Yu has a long standing interest in studying the molecular mechanisms of drug disposition and multidrug resistance in Cancer Pharmacology and Therapy. He has demonstrated a track record in the investigation of drug metabolism (DM), pharmacokinetics (PK), and pharmacodynamics (PD) essential for the development of new therapeutics and exercise of precision medication, which also requires accurate and reliable quantification of drugs/metabolites in complex biological matrix. Ongoing research in Dr. Yu laboratory focuses on noncoding RNA pharmacoepigenetics and the ultimate goal is to translate noncoding microRNA to new therapeutics. In particular, current efforts are directed to the investigation of (a) the mechanistic actions of microRNAs in the regulation of cancer cellular processes (e.g., drug disposition and tumor progression), (b) novel RNA bioengineering technologies, and (c) bioengineered noncoding RNAs as cancer therapeutics.

**ASPET Member Since:** 2007



**ASPET Activities:**

- Councilor, Division for Drug Metabolism (2010–2013)
- Session Chair, Division for Drug Metabolism Symposium, ASPET Annual Meeting at EB in Washington, DC (2011)
- Councilor, Upstate New York Pharmacology Society (2011-2012)
- President, Upstate New York Pharmacology Society (2012-2013)
- Past President, Upstate New York Pharmacology Society, (2013-2014)
- Session Chair, Division for Drug Metabolism Symposium, ASPET Annual Meeting at EB in Boston, MA (2013)
- Information Officer, Division for Drug Metabolism (2013–2015)
- Editorial Board, *Drug Metabolism and Disposition* (2014-present)

**Other Society Memberships/Activities:**

- Member, International Society for the Study of Xenobiotics (2000-2012)
- Member, American Association of Pharmaceutical Scientists (AAPS) (2004-2012)
- Session Chair, AAPS Annual Meeting (2005)
- Committee Chair for volunteers, PPDM, American Association of Pharmaceutical Scientists (2006-2009)
- Open Forum Committee member, PPDM, American Association of Pharmaceutical Scientists (2009-2011)
- Session Chair, AAPS - NERDG Annual Symposium (2011)
- Session Chair, MDO meeting (2012)
- Session Chair, AAPS Annual Meeting (2014)
- Chair, Meeting Organizing Committee, MDO (2016)

**Division for Drug Metabolism Secretary/Treasurer-Elect - Hyunyoung (Young) Jeong****Degrees/Institutes/Years Earned:**

- PharmD, University of Illinois at Chicago, 2001
- PhD, University of Illinois at Chicago, 2004

**Administrative Accomplishments:**

Since Young joined the University of Illinois at Chicago as a faculty member in 2006, she served and chaired multiple Department-, College-, and University-level committees, including research grant review committees and Animal Care Committee. Young is currently the Director of Graduate Education for the College, and a member of Advisory Board for Building Interdisciplinary Research Careers in Women's Health (BIRCWH) training program at UIC. Young served organizing committees for various drug metabolism meetings including Metabolism and Drug Oxidation, and chaired multiple scientific symposiums at meetings such as Experimental Biology and International Society of Studies of Xenobiotics. Young served as councilor of the Division for Drug Metabolism from 2013 - 2016.

**Research Areas:**

The long-term goal of Young's research program is to identify and characterize factors modulating drug disposition and better understand sources underlying variability in drug pharmacokinetics (PK), to provide a solid knowledge base to achieve precision medicine. So far, Young's research program has focused on two major topics: (1) mechanisms for altered drug metabolism during pregnancy and (2) molecular basis of interindividual variability in CYP2D6-mediated drug metabolism. Her current research programs are funded by two R01 grants from NIH. Additionally, as a co-investigator on multiple NIH-funded projects, Young has provided her expertise in drug metabolism and PK for development of antiviral and antimicrobial agents. Young has published over 45 papers in drug metabolism, molecular pharmacology, and PK field.

**ASPET Member Since:** 2006

**ASPET Activities:**

- Division for Drug Metabolism
- Editorial Board member, *Drug Metabolism and Disposition*

**Other Society Memberships/Activities:**

- ISSX

**Division for Drug Metabolism Secretary/Treasurer-Elect - Jed Lampe**

**Degrees/Institutes/Years Earned:**

- BS, Walla Walla University, 1992
- MS, Idaho State University, 1999
- PhD, University of Washington, 2007

**Administrative Accomplishments:**

As an assistant professor at the University of Kansas Medical Center, I have served on a number of academic and professional committees, co-chaired a symposium at ASPET Annual Meeting at EB2016, and co-chaired a regional NMR conference. In 2016, I served as co-chair of the ASPET Annual Meeting at EB Symposium entitled "*Substrate Modulation of Organic Anion and Cation Transporters*". Additionally, I have co-chaired the GRASP (Great Plains Regional Annual Symposium on Protein and Biomolecular NMR) from 2012-2016, inclusive. For the KU School of Medicine, I have served as Vice-Chair and Chair (subsequent years) of the Academic Promotions Committee and as a member of the KU School of Medicine elections committee. Additionally, I have served as an Annual Graduate Student Research Forum Judge (from 2012-2016, inclusive), and as faculty mentor for our KU SOM graduate student recruitment weekend (from 2012-2014, inclusive). I believe that an individual must give back to their institution and their broader community. Hence, I have a commitment to service at the institutional, regional, and national level.

**Research Areas:**

Currently, there are two major research initiatives in the Lampe lab:

*1. Understanding the role of cytochrome P450 CYP3A7 in drug metabolism and toxicity in the infant.*

The liver metabolizes the vast majority of the drugs that enter our bodies, yet there are significant developmental differences between infant and adult livers. Cytochrome P450 CYP3A7 is the most abundant drug detoxifying enzyme expressed in infants from before birth until 6 months of age, yet little is known of its role in metabolizing many common drugs that are given to newborns. Therefore, it is our goal to structurally and functionally characterize this enzyme in order to better understand its important role in pediatric drug metabolism.

*2. Determining the mechanism of substrate binding and translocation in organic cationic drug transporters.*

The human organic cation transporter 1 (OCT1) is an important polyspecific transporter involved in the uptake and transport of a wide variety of cationic drugs. It is the most abundant drug transporter expressed in the neonate and developing infant, making it a likely target for potential drug-drug interactions. Our goal is to understand the structural and functional characteristics of OCT1 in hopes of using this knowledge to improve cationic drug discovery and design.

**ASPET Member Since:** 2015

**ASPET Activities:**

- Symposium Co-Chair, ASPET Annual Meeting at EB2016 in San Diego, CA
- Judge, Student Poster Competition (2016)
- Reviewer, *Drug Metabolism and Disposition*
- Member, Division for Drug Metabolism

**Other Society Memberships/Activities:**

- Member, American Chemical Society, National and Local (Kansas City) section
- Member, Division of Medicinal Chemistry, American Chemical Society

## **Division for Molecular Pharmacology Chair-Elect - J. Silvio Gutkind**

**Degrees/Institutes/Years Earned:**

- MSc, Pharmacy, University of Buenos Aires, 1980
- MSc, Biochemistry, University of Buenos Aires, 1983
- PhD, Pharmacy and Biochemistry, University of Buenos Aires, 1985

**Administrative Accomplishments:**

I joined the NIDCR, NIH, where I was a Branch Chief (1998-2015) until our team's recent relocation to UCSD. At the NIH, we launched a vibrant and highly productive international

collaborative cancer research program, with emphasis on novel molecular mechanisms in cancer. I have also had the opportunity to contribute to multiple review panels, including NIH study sections (NDT, 2014-2007; ICI, 2007; MIST, 2008; TME, 2008-2012) and NCI and NIGMS special emphasis panels. I have served in multiple national and international advisory boards, including the Max Planck Institute (Germany) and Israel Cancer Foundation. I have also co-organized numerous meetings (see below), including a series of signal transduction and molecular medicine meetings in South America (2010/12/15) that has provided unique opportunities for advanced training of junior scientists in the region, and the initiation of new international collaborative efforts.

*Selected meetings and symposia organized:*

- Keystone Winter Symposia, "Oncogene Networks" (1999)
- Co-chair, Gordon Research Conference, "Phosphorylation & G-Protein Mediated Signaling Networks", Biddeford, Maine (2008)
- Co-Organizer, South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM, Argentina (2010, 2012, 2015)
- Co-Organizer, Global Cancer Forum, New York City, NY (2016)
- Co-organizer, Symposium on Cancer Stem Cells as Pharmacological Targets, ASPET Annual Meeting at Experimental Biology, San Diego, (2016)

**Research Areas:**

Our laboratory has pioneered the study of the role of G protein coupled receptors, G proteins, and their signaling networks, in human neoplasia. We have focused on the study of the potent oncogenic activity of GPCRs and G proteins, including virally-encoded GPCRs, to dissect the signaling circuitries regulating normal and aberrant cell proliferation, cancer progression, tumor-induced angiogenesis, and metastasis. We are now investigating the mechanisms by which genetic mutations in G $\alpha$ q proteins initiate uveal and cutaneous melanoma, the role of G $\alpha$ s and its target, PKA, in cancer, and how mutations and autocrine activation of GPCRs contribute to tumor progression, immune evasion, and therapy resistance. In parallel, we are exploring the role of the mTOR pathway in cancers of the oral cavity, a disease that results in 250,000 deaths each year worldwide. We are now investigating the effectiveness and mechanism of action of PI3K/mTOR inhibitors for oral cancer prevention and treatment, as single agents and as part of novel signal transduction-based co-targeting strategies. Ultimately, the goal of our research program is to exploit the emerging information on dysregulated signaling circuitries and individual genomic and molecular alterations to identify new therapeutic options to prevent and treat cancer.

**ASPET Member Since:** 2015

**ASPET Activities:**

- Member, Executive Committee, Division for Molecular Pharmacology (2015-present)
- Member, Editorial Advisory Board, *Molecular Pharmacology* (2015-present)
- Chair, Symposium on "Cancer Stem Cells as Pharmacological Targets" presented at the ASPET Annual Meeting at Experimental Biology (2016)

**Other Society Memberships/Activities:**

- Member, American Society of Molecular Biology (ASMB)
- Member, International Association for Dental Research (IADR)
- Founding Member, International Academy of Oral Oncology (IAOO)
- Recent Awards:
  - Pharmaceutical Research and Manufacturers of America (PhRMA), Research & Hope Award for “Excellence in Academic Research”, for “pioneering studies on the potent oncogenic activity of G proteins and GPCR (G protein-coupled receptors), which ultimately led to novel strategies for treating and preventing many types of cancer” (2015)
  - Keynote Lecture, ASPET Upstate New York Pharmacology Society 4th Annual Meeting, Rochester, NY (2015)
  - Keynote Lecture, American Head and Neck Society (AHNS) Annual Meeting (2014)
  - Pan-American Association for Biochemistry and Molecular Biology Lecture, Madrid, Spain (2013)
  - Elliot Osserman Award, Israel Cancer Research Foundation (2012)

## Division for Molecular Pharmacology Chair-Elect - Tracy Handel

### Degrees/Institutes/Years Earned:

- BS, Chemistry, Bucknell University, 1980
- PhD Chemistry, California Institute of Technology, 1989

### Administrative Accomplishments:

My most important prior administrative accomplishment was as Chair of the Biomedical Sciences (BMS) PhD Program (2010-2013, Vice Chair 2008-2010). In this position, I oversaw a program of ~200 faculty and ~200 students that comprise laboratories throughout UCSD Health Sciences (School of Medicine and SSPPS), the Sanford Burnham Research Institute, Scripps Research Institute, Salk Institute and La Jolla Institute for Allergy and Immunology. Major responsibilities included monitoring student progress, and resolving problems with students, faculty and program operations, recruiting faculty to serve on various subcommittees, and serving on most of the committees myself. These committees included: (i) Admissions; (ii) Faculty Membership; (iii) The Student Standing, Promotions and Advisory Committee which provides an advisory system for the students and evaluates progress of all students in the program at least twice a year; (iv) The Research Proposition Committee which administers the Research Proposition Qualifying Exam; (v) The Curriculum Committee; and (vi) The Diversity Committee. Examples of other administrative duties include: my current position as Chair, Division of Pharmaceutical Sciences, SSPPS (2016-pres); First Faculty Chair in SSPPS (2008-2010); Chemokines Gordon Conference Chair 2014-2016 and Vice Chair 2012-2014; Co-Chair Molecular Biophysics Training Grant Program (2014-pres); Co-Chair Pharmacology Training Area in the BMS program (2015-pres); other.

### Research Areas:

My laboratory takes a multidisciplinary approach (cell biology, biophysics, structural biology) to

study chemokines and chemokine receptors (which are GPCRs). These proteins play critical roles in cell migration but are also major players in numerous diseases (e.g. inflammation, cancer and HIV). Our most significant recent accomplishment was the structure determination of a complex involving chemokine receptor CXCR4 with chemokine (Qin et al., Science 2015). This structure provided the first glimpse of how chemokines bind and activate their receptors, and enabled us to predict structural and functional details of many other chemokine receptor complexes. Together with researchers from Integral Molecular, we also defined a contiguous signaling pathway from chemokine to G protein through the transmembrane helices of CXCR4 (Wescott et al., PNAS 2106). We are also pursuing structure and structure-function studies of several other receptor:chemokine complexes and utilizing techniques such as single molecule fluorescence to understand the dynamics and activation mechanisms of these receptors. Finally, we have recently solved the structure of receptor CCR2 simultaneously bound to an orthosteric and allosteric antagonist, where the allosteric ligand binds at the G protein-binding site and is inhibitory through multiple mechanisms; we plan to take pursue similar studies of chemokines receptors with small molecules for drug discovery.

**ASPET Member Since:** 2016

**Other Society Memberships/Activities:**

- Member, American Society for Biochemistry and Molecular Biology
- Member, Association for the Advancement of Science
- F1000

**Division for Molecular Pharmacology Secretary/Treasurer-Elect - Yang (Kevin) Xiang**

**Degrees/Institutes/Years Earned:**

- PhD, Oregon Health Science University, 2000

**Administrative Accomplishments:**

I have been involved in administrative activities since my undergraduate training time. I have served the committees including graduate student organization (GSO) in OHSU. At postdoc training period, I founded and served as the first chair of CLIPSS in Stanford University, which now has more than 200 members. After becoming an independent faculty member, I have served numerous committees at international, national, campus, school and department levels, including internalization meeting organization, research committee, biosafety committee, education and curriculum committee, admission and advisor committee, faculty search, mentoring, and advisory committee. Overall, I can bring broad experience and expertise to serve the ASPET molecular Division.

**Research Areas:**

My current research focuses on insulin resistance associated with aging/stress-related metabolic disorders and diseases such as type 2 diabetes, diabetic cardiomyopathy, and Alzheimer's disease. We have recently characterized a novel insulin receptor and beta-adrenergic receptor network expressed in different tissues. This opens a new field to understand insulin resistance in glucose metabolism as well as in a broad range of cardiovascular complications associated with diabetes and metabolic disorders. One of the major goals is to understand prevalent co-existence of insulin resistance and adrenergic dysregulation in a variety of diseases. We utilize a wide range of tools from single molecular analysis of receptor complexes, high resolution of living cell imaging, to in vivo genetic, surgical, and pharmacological manipulation. By combining development of novel analytical tools with in vivo and in vitro characterization of receptor signaling and function, we hope to eventually provide novel strategies on clinical therapies for metabolic and cardiovascular conditions.

**ASPET member since:** 2009

**ASPET Activities:**

- Attended ASPET Annual Meeting at Experimental Biology since 1998
- Published in *Molecular Pharmacology* as the first author and senior author
- Reviewer, *Molecular Pharmacology*
- Reviewer, *Journal of Pharmacology and Experimental Therapeutics*

**Other Society Memberships/Activities:**

- American Heart Association
- American Diabetes Association
- American Society of Cell Biology
- American Society of Biochemistry and Molecular Biology

**Division for Pharmacology Education Chair-Elect - A. Laurel Gorman****Education:**

- BS, University Florida
- PhD, Pharmacology and Therapeutics, Louisiana State University
- Post-doctoral academic training, Weill Cornell School of Medicine, Miami Project of the University of Miami School of Medicine

**Administrative Accomplishments:**

Within the ASPET Division for Pharmacology Education, I am currently serving on the executive committee. With over 16 years of experience teaching pharmacology to various health professional students, I have won numerous teaching awards recognizing my innovation and dedication to pharmacology education. Within my current institution, I have been the founding co-director and currently direct the preclinical pharmacology curriculum at the



emerging University Of Central Florida College Of Medicine (UCF COM). In other leadership roles, I currently serve as the co-director of the Endocrine-Reproductive Module, the Chair of the UCF COM Student Evaluation and Progress Committee, and I am an elected senator representing the COM in the UCF faculty senate. I also serve as the medical education department representative on the UCF Diversity and Inclusion Council. Previously, I chaired our founding faculty pharmacology search committee as well as the UCF COM Medical Education 5 year strategic planning initiatives council. As a founding faculty for a new school constantly developing new programs, I have served my institution in many other critical administrative ways, including serving as a core team member developing 8 preclinical modules as well as representing the second year systems modules on the UCF COM Curriculum Committee and Program Evaluation Committees. I enjoy working and leading groups in inclusive and collaborative environments and look forward to serving in a leadership role for the ASPET DPE.

### **Research Areas:**

As a basic science researcher, I published several manuscripts on the topics of neuropharmacology of drugs of abuse and pain research. However, I transitioned into medical education research when I accepted an educator tract faculty position, and I have developed medical education research projects evaluating the value and best methods for promoting the active learning of pharmacology thorough innovative techniques like high fidelity simulations and games. Currently I am a co-investigator on 2 medical education grants exploring the topics of collaborative learning in preclinical simulations and processes of integrating geriatrics pharmacology education into clerkship teaching. I have published several manuscripts on my educational research in peer-reviewed journals and presented nationally, by peer-reviewed invitation, at top medical educational meetings, including the ASPET teaching Institute and educational symposia, International Association for Medical School Educators (IAMSE), International Medical Simulations in Healthcare (IMSH), and the Groups on Educational Affairs of the AAMC (SGEA and GEA of AAMC). In recognition for the exceptional quality of my simulations research, I have been awarded the UCF Scholarship in Teaching and Learning Award, an ASPET DPE travel award, and top research presentations awards from the IMSH and the SGEA of the AAMC meetings.

### **ASPET Member Since: 2010**

#### **ASPET Activities:**

- Member, Division of Pharmacology Education (2010-present); Executive Committee (2015-2018)
- Pharmacology Educator Award, Division for Pharmacology Education (2013)
- Presenter, ASPET Teaching Institute: Educational games and teaching innovations sessions (2014)
- Presenter and Co-Chair, Division for Pharmacology Education Collaborative learning session (2015)
- Executive Committee, Division for Pharmacology Education (2015-2018)
- Inducted into the Division for Pharmacology Education Academy of Educators (2016)
- Member, Division for Neuropharmacology
- Member, Division for Behavioral Pharmacology



**Other Society Memberships/Activities:**

- Member and annual reviewer for meeting abstracts and review papers, National and Southern Groups on Educational Affairs (GEA and SGEA) & Research in medical Education (RIME) of the AAMC
- Member, IAMSE (2012-current); Nominated for IAMSE executive board (2015)
- Reviewer of abstracts for annual meeting and the *Medical Science Educator*, IAMSE
- Member, IAMSE Meeting Programming Committee (2012, 2018 meetings)
- Editorial Board, *Medical Education On-line*
- Reviewer, *Advances in Physiology Education*
- Reviewer, *Teaching and Learning in Medicine*
- Reviewer, *AAMC Med Ed Portal*
- Member, Generalists in Medical Education
- Member, Association for Women in Science
- Member, Pharmacology Professionals

**Division for Pharmacology Education Chair-Elect - Helmut Gottlieb****Degrees/Institutes/Years Earned:**

- BS, 1998
- PhD, 2004

**Administrative Accomplishments:**

As a founding faculty at the Feik School of Pharmacy (FSOP), I have taken upon many roles which includes academic and research procedures. I am the current elected chair of the FSOP Rank and Tenure Committee. I was an active member of two main campus executive committees involved in establishing and managing NIH extramural funding and Interprofessional education grants, which helped shape policy establishing IACUC and an animal research facility on our campus, and helped design and manage facility renovations. I also managed my own extramural NIH funded grant, which included finance and budget lines, technician salary and reports, and multiple students research. In addition to those responsibilities, I have served on several search committees, at present I am a member of the FSOP Dean Search Committee. I have also served on assessment, admission, curriculum, strategic planning, graduate council, faculty development, and research advisory committees. Additionally, I am also the course coordinator for several pharmacology courses taught at the pharmacy, nursing, and optometry schools.

**Research Areas:**

The focus of my research is to characterize the impact of central nervous system (CNS) endogenous opioid systems on the neural circuitry associated with the development and maintenance of high blood pressure in an *in vivo* Angiotensin II-High Salt diet hypertension model. Considerable effort has been devoted to understanding the role of kappa opioids in vasopressin secretion, however, its effects on sympathetic activity and sodium excretion have

not been fully explored. This is of interest since essential hypertension usually involves activation of the renin-angiotensin-aldosterone system, and increases in sympathetic activity and urinary sodium retention, which the latter two physiological effects have been shown to be modulated by kappa opioid receptors. Significant preliminary data indicates that endogenous central kappa opioid systems play a role under certain pathophysiological conditions. However, its physiological effects appear to change with the development of hypertension. Although considerable evidence suggests a role for opioid systems in cardiovascular and renal function, its precise CNS sites, mechanisms and pathways are yet to be determined. As such, my lab utilizes *in vivo*, molecular biology, and electrophysiology techniques to examine the interplay role of the kappa opioid systems under Angiotensin II-High Salt hypertension model.

**ASPET Member Since: 2008**

**ASPET Activities:**

- Diversity Committee/Committee on Mentoring and Career Development (2011-2016)
- Division for Pharmacology Education (2011-present)

**Other Society Memberships/Activities:**

- American Physiological Society (2005-present)
- American Association of Colleges of Pharmacy (2007-present)
- Kappa Psi Pharmaceutical Fraternity (2009-present)
- The Rho Chi Pharmaceutical Honor Society (2011-present)
- Phi Lambda Sigma Pharmacy Leadership Society (2011-present)
- International Physiology Committee, American Physiological Society (2014-present)

**Division for Pharmacology Education Secretary/Treasurer-Elect - Shafiqur Rahman**

**Education:**

- BS, Pharmacology with Honors, School of Medicine, Dhaka University
- MS, Pharmacology, School of Medicine, Dhaka University
- PhD, Neuropharmacology, School of Medicine, Memorial University of Newfoundland

**Administrative Accomplishments:**

- Research Associate, Department of Psychiatry, Indiana University School of Medicine (1998-2001)
- Research Scientist/Assistant Professor, Department of Psychiatry and Center for Addiction and Mental Health, University of Toronto (2001-2005)
- Senior Research Scientist, Center for Drug Research and Translational Science, University of Kentucky (2005-2007)
- Assistant/Associate Professor of Pharmacology, Department of Pharmaceutical Sciences, College of Pharmacy, (2007-2013)
- Professor of Pharmacology, Department of Pharmaceutical Sciences, College of Pharmacy, SDSU (2014-Present)

- Chair, Graduate Education and Research Committee, College of Pharmacy, SDSU (2015-Present)
- Vice President, Council of Higher Education-SDSU Chapter (2013-2016)
- Co-Director, Inter-professional/Inter-departmental education, College of Pharmacy, SDSU (2015-present)
- Course Director for PharmD and graduate level pharmacology courses/curriculum, College of Pharmacy, SDSU (2010-Present)
- Chair, Academic Affairs Committee, SDSU, responsible for providing oversight for curriculum management and innovation across University campus, including pharmacy/pharmacology curriculum (2013-2015)
- Academic Leadership Fellow, American Association of Colleges of Pharmacy (AACCP) (2015-2016)

**Research Areas:**

Pharmacology Educational Research and Scholarship: Dr. Rahman's educational research focuses on curriculum development and innovations, such as competency-based pharmacology education and creative approaches to delivery of pharmacology knowledge in the classroom. In addition, he is interested in exploring contextual factors how inter-professional education leads to improved long-term outcomes in differing circumstances in pharmacy and allied health professions. He is currently serving as co-director for inter-departmental education research program in the college.

Laboratory Research: Dr. Rahman's research laboratory focus is drug discovery in neuropharmacology, i.e., the development of novel therapeutic drug candidates for the treatment of alcohol or nicotine addiction and co-morbid neuropsychiatric disorders. In particular, the primary focus is the discovery of subtype-selective neuronal nicotinic receptor ligands as novel therapeutic drug candidates for alcohol or nicotine use disorders and co-morbid anxiety or major depressive disorder using animal models.

**ASPET Member Since:** 2006

**ASPET Activities:**

- Member, Division for Pharmacology Education
- Member, Division for Behavioral Pharmacology
- Member, Division for Neuropharmacology
- Judge, Division for Behavioral Pharmacology Poster Competition (2009-2014)
- Reviewer, Summer Undergraduate Research Fellowship Awards Program (2011-2013)
- Member, Executive Committee, Division for Pharmacology Education (2012-present)
- Member, ASPET Program Committee, Division for Pharmacology Education (2015-present)

**Other Society Memberships/Activities:**

- Fellow, American Foundation for Pharmaceutical Education
- Member, Society for Neuroscience
- Member, American Association of Colleges of Pharmacy

- Member, American Association of Pharmaceutical Scientists
- Co-Chair, AACP Self-Study and Assessment Committee, College of Pharmacy, SDSU (2012-2014)
- Editorial Advisory Board, *Journal of Addiction Research and Therapy* (2010-present)
- Editorial Advisory Board, *Current Drug Abuse Reviews* (2009-present)
- Editor, *Brain as a Drug Target* (2011)
- Editor, *Molecular Basis of Drug Addiction* (2016)
- Associate Editor-in-Chief, *CNS and Neurological Disorders-Drug Targets* (2016-present)

## Division for Pharmacology Education Secretary/Treasurer-Elect - Arun Ram

### Degrees/Institutes/Years Earned:

- MBBS, Medicine and Surgery, Dr. MGR University, 1998
- MD, Medicine, Dr. MGR University, 2002

### Administrative Accomplishments:

- Successfully rolled out the Foundational Sciences-II module in the Eastern Virginia Medical School, Norfolk, VA working in collaboration with faculty from various disciplines across basic and clinical sciences in the new integrated MD curriculum.
- In my role as the Course Director of Clinical Pharmacology for the MPA program, I completely revamped the traditional lecture based classes to flipped classes resulting in both superior results compared to the previous years and excellent feedback from the students.
- Improved the first time pass-rate for the school from 80% to 95 – 100% within 2 years as the Chairperson of the med school Curriculum and as the Associate Director of Center for Excellence in Medical Education in St. Matthews University. I had the privilege to plan, organize, co-ordinate multiple local and international CMEs and conferences liaising with physicians, pharmacists, students and faculty efficiently.

### Research Areas:

- Medical Education Research:
  - **Mehnaatamai Mohanram A**, Zhong Q, Singh TD, Jagadeesh A, Evaluating the Effectiveness of Pretest and posttest Model of Active Learning in a Medical School. *FASEB J.* April 2015 29:928.4
  - Qing Zhong, **Arun Mehnaatamai Mohanram**, Comparison of learning resources for Medical Pharmacology in a Caribbean Medical School. *MedEdPublish* 2015, 4:8
  - **Arun Mehnaatamai Mohanram** and Qing Zhong. Assessing team-based learning method's effectiveness in medical pharmacology teaching. *FASEB J.* April 2014 28:719.8.
  - Qing Zhong, **Arun Ram**, Learning Medical Pharmacology: A Survey of students' perceptions and experience. Poster Presentation; IAMSE 2014, Nashville, TN.
- Scientific Research:

- **M Ram**, M. Khalid, A. Jagadeesh, L.E. Maroun, "Interferon-alpha response element found for the B-cell translocation gene on human chromosome 21." Annual Meeting of the American College of Clinical Pharmacology 2013, Bethesda, MD.
- U Senthilkumar, **Arun Mohanram**. Allopathic and Ayurvedic Approaches in Management of Vitiligo. *FASEB J.* April 9, 2013 27:890.13
- **Arun M M**, "A Study on The Effect of Spirulina (blue green algae) on Blood Glucose Level of Alloxan Induced Diabetic Rats." Won II prize for best oral presentation; Southern Regional Conference of IPS 2001.

**ASPET Member Since:** 2014

**ASPET Activities:**

- Poster presenter, ASPET Annual Meeting at Experimental Biology (2013, 2014 and 2015)
- Attendee, Executive Committee Meeting (2015)


**Other Society Memberships/Activities:**

- Member, American College of Clinical Pharmacology (ACCP) (2010-present)
- Member, ACCP Education Committee (2014-present)
  - As an active member, I am extensively involved in writing, reviewing and conducting educational activities including monthly ACCP Journal activities and moderating multiple ACCP's worldwide webinar / virtual journal club meetings

## *Bylaws*

### **Division for Drug Metabolism Name Change**

**Group Requirement:** DM



The division executive committee and membership in attendance at the last division business meeting voted to change the division name to **Division for Drug Metabolism and Disposition**. The rationale was that this name was more inclusive. We are now seeking approval from the broader division membership. Once approved, the division will submit the name change to the ASPET Council for final approval.

Do you approve changing the name of the division from Division for Drug Metabolism to Division for Drug Metabolism and Disposition?

Yes  
No